Shares of Cryo-Cell International, Inc. (NYSEAMERICAN:CCEL - Get Free Report) passed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $0.00 and traded as high as $8.11. Cryo-Cell International shares last traded at $7.90, with a volume of 10,741 shares trading hands.
Cryo-Cell International Trading Down 0.8 %
The stock has a market cap of $63.15 million, a price-to-earnings ratio of -7.39 and a beta of 0.49.
Cryo-Cell International (NYSEAMERICAN:CCEL - Get Free Report) last posted its quarterly earnings data on Tuesday, October 15th. The company reported $0.13 earnings per share for the quarter, topping the consensus estimate of $0.02 by $0.11. Cryo-Cell International had a negative return on equity of 42.06% and a negative net margin of 28.03%. The firm had revenue of $8.07 million for the quarter.
Cryo-Cell International Announces Dividend
The company also recently disclosed a -- dividend, which was paid on Friday, November 29th. Shareholders of record on Friday, November 15th were paid a dividend of $0.25 per share. The ex-dividend date was Friday, November 15th. Cryo-Cell International's payout ratio is -94.34%.
Hedge Funds Weigh In On Cryo-Cell International
A hedge fund recently raised its stake in Cryo-Cell International stock. Geode Capital Management LLC lifted its stake in shares of Cryo-Cell International, Inc. (NYSEAMERICAN:CCEL - Free Report) by 68.5% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 39,860 shares of the company's stock after buying an additional 16,203 shares during the period. Geode Capital Management LLC owned about 0.49% of Cryo-Cell International worth $254,000 as of its most recent SEC filing. 10.44% of the stock is currently owned by institutional investors and hedge funds.
About Cryo-Cell International
(
Get Free Report)
Cryo-Cell International, Inc engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, auto-immune diseases, multiple sclerosis, Alzheimer's disease, Parkinson's diseases.
Featured Stories
Before you consider Cryo-Cell International, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cryo-Cell International wasn't on the list.
While Cryo-Cell International currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
